Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$44.82 USD

44.82
11,316,753

-1.03 (-2.25%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $44.83 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Zacks Equity Research

Bristol-Myers (BMY) Q4 Earnings & Sales Beat, Stock Gains

by Zacks Equity Research

Bristol-Myers' (BMY) fourth-quarter 2023 earnings and sales surpass estimates as Reblozyl and Revlimid outperform. Shares rise on the same.

Zacks Equity Research

Nonfarm Payrolls Increased More Than Expected

by Zacks Equity Research

Nonfarm Payrolls Increased More Than Expected

Mark Vickery headshot

BLS Jobs Up Big: 353K, 3.7% Unemployment

by Mark Vickery

353K new jobs created for January are nearly double the 180K or so analysts were looking for.

Zacks Equity Research

Compared to Estimates, Bristol Myers (BMY) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Bristol Myers' (BMY) sBLAs for Breyanzi Get FDA Priority Tag

by Zacks Equity Research

Bristol Myers' (BMY) two sBLAs for Breyanzi in relapsed/refractory follicular lymphoma and relapsed/refractory mantle cell lymphoma receive FDA acceptance and priority review.

Zacks Equity Research

2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up

by Zacks Equity Research

2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.

Zacks Equity Research

Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Wall Street's Insights Into Key Metrics Ahead of Bristol Myers (BMY) Q4 Earnings

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Bristol Myers (BMY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

Zacks Equity Research

Bristol Myers Squibb (BMY) Increases Yet Falls Behind Market: What Investors Need to Know

by Zacks Equity Research

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $49.87, denoting a +0.34% change from the preceding trading day.

Zacks Equity Research

Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

What You Need to Know Ahead of Bristol-Myers (BMY) Q4 Earnings

by Zacks Equity Research

Investors are likely to focus on Opdivos demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.

Ekta Bagri headshot

FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels

by Ekta Bagri

The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.

Zacks Equity Research

Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

The latest trading day saw Bristol Myers Squibb (BMY) settling at $49.57, representing a -1.08% change from its previous close.

Zacks Equity Research

Exelixis (EXEL) Outperforms on Cabometyx and Pipeline Progress

by Zacks Equity Research

Exelixis' (EXEL) lead drug, Cabometyx, maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.

Zacks Equity Research

Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $50 in the latest trading session, marking a -0.62% move from the prior day.

Zacks Equity Research

Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC

by Zacks Equity Research

Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.

Andrew Rocco headshot

Bullish Continuation in '24? 3 Market Areas to Watch

by Andrew Rocco

Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.

Zacks Equity Research

Prothena's (PRTA) Update on Pipeline Progress Disappoints

by Zacks Equity Research

Prothena (PRTA) provides updates on PRX012, PRX123, birtamimab and other programs. The delay in phase III data on birtamimab disappoints investors.

Zacks Equity Research

Here's Why Bristol Myers Squibb (BMY) Fell More Than Broader Market

by Zacks Equity Research

Bristol Myers Squibb (BMY) concluded the recent trading session at $51.28, signifying a -0.98% move from its prior day's close.

Zacks Equity Research

Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis

by Zacks Equity Research

Cytokinetics (CYTK) shares gain on reports of acquisition by pharma giant Novartis.

Sweta Killa headshot

Biotech ETFs Stage Solid Comeback at the Start of 2024

by Sweta Killa

The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.

Zacks Equity Research

Exelixis (EXEL) Posts Preliminary 2023 Results, to Cut 13% Jobs

by Zacks Equity Research

Exelixis (EXEL) posts preliminary results for 2023 and issues 2024 guidance. The company is set to cut its workforce by 13% in the first quarter of 2024.

Zacks Equity Research

Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study

by Zacks Equity Research

Data from a late-stage study shows that non-transfusion-dependent thalassemia patients who received Agios' (AGIO) mitapivat demonstrated a statistically significant increase in hemoglobin response.

Zacks Equity Research

Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More

by Zacks Equity Research

Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.

Zacks Equity Research

Bristol Myers Squibb (BMY) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) concluded the recent trading session at $52.30, signifying a -0.87% move from its prior day's close.